Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

Date 27 September 2015
Event European Cancer Congress 2015
Session Immunotherapy in Cancer II
Topics Cancer Immunology and Immunotherapy
Presenter Ott, P.